A federal courtroom in Chicago has become the focal point of a legal dispute over the fate of millions of genetic screening results: plaintiffs say a health artificial intelligence company used and sold DNA data without the consent of the people who provided it, and that genetic information cannot be reliably stripped of identifiers.
The dispute in brief
Multiple putative class action lawsuits filed in Chicago federal court allege that Tempus AI sold genetic information drawn from an acquired database containing the results of millions of screening tests. The complaints contend the company lacked consent to use and to share those data with pharmaceutical companies.
What the complaints allege
- The lawsuits assert that Tempus AI sold genetic information from a database it acquired that holds results from millions of screening tests.
- Plaintiffs allege the company did not obtain consent to use or to share those genetic data with pharmaceutical firms.
- According to the complaints, genetic data resists attempts to de-identify it, undermining claims that the information can be anonymized before commercial use.
Why the plaintiffs' de‑identification claim matters
The complaints hinge on two linked facts they present: the scale of the database and the asserted difficulty of de‑identifying genetic material. If genetic information cannot be reliably de‑identified, then selling or sharing it without consent would raise central questions about privacy protections and the legal grounds for commercial use. The plaintiffs’ contention that identifiability persists frames the core legal and ethical challenge the court will now consider.
Broader implications and unanswered questions
The lawsuits set up competing priorities: commercial uses of genetic data for research and product development versus individual consent and privacy. Because the complaints emphasize both the volume of data involved and the limits of de‑identification, the case will likely be watched for how courts interpret consent and identifiability in the context of large genetic databases. For people whose test results may be included in such databases, and for organizations that build products from those data, the litigation raises a basic question: when genetic information is treated as commercially valuable, what protections follow for the individuals it originates from?
